Journal Scans
Incidence, Presenting Features and Outcome of Extramedullary Disease in Multiple Myeloma: A Longitudinal Study on 1003 Consecutive Patients
HDT Not Implicated in Increased Extramedullary Multiple Myeloma
M Varettoni, A Corso, G Pica, S Mangiacavalli, C Pascutto, M Lazzarino
20090101
2009 Feb 1
Ann Oncol
Incidence, Presenting Features and Outcome of Extramedullary Disease in Multiple Myeloma: A Longitudinal Study on 1003 Consecutive Patients
Ann Oncol. 2009 Feb 1;21(2):325-330, M Varettoni, A Corso, G Pica, S Mangiacavalli, C Pascutto, M Lazzarino
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
An Italian study has confirmed that the incidence of extramedullary (EM) multiple myeloma is increasing, but not, as some suspected, because of the expanded use of high-dose therapy (HDT) or new biologic agents such as thalidomide, bortezomib, and lenalidomide. Varettoni et al. analyzed the cumulative incidence of EM disease, the possible relationship between the use of HDT or new biologics and EM spread, and the prognostic impact of EM disease in 1003 consecutive multiple myeloma patients diagnosed...
